Method and apparatus for performing assays

Information

  • Patent Grant
  • 9229001
  • Patent Number
    9,229,001
  • Date Filed
    Tuesday, November 23, 2010
    13 years ago
  • Date Issued
    Tuesday, January 5, 2016
    8 years ago
Abstract
An apparatus is provided for performing an chemical, biochemical, or biological assay on a sample comprising: a microfluidic assay cartridge (1) that contains at least one sample inlet well (2) configured to receive a sample; and a microfluidic sub-unit (3) associated with the microfluidic assay cartridge (1) and comprising microfluidic channels (8), micro-valves (4, 4a, 9) and at least one separate and fluidicly-isolated isolation channel (5), and at least one hollow element (14); the at least one hollow element (14) being functionalized with a capture moiety or molecules (15) so as to form at least one reaction vessel (19); the microfluidic channels (8) and micro-valves (4, 4a, 9) configured to respond to signaling containing information about performing the assay and to controllably receive the sample and at least one reagent in the at least one reaction vessel (19), and to provide from the at least one reaction vessel (19) light containing information about the assay performed on the sample inside the at least one reaction vessel (19) as a result of said at least one reagent.
Description
BACKGROUND OF THE INVENTION

1. Field of the Invention


The present invention relates to a method and apparatus for performing assays; and more particularly relates to a method and apparatus for performing chemical, biological or biochemical assays using microfluidic technology.


2. Brief Description of Related Art


One of the primary factors affecting the data quality of a multiplexed system is biological cross reactivity, which is caused when multiple analytes and a multi-reagent detection cocktail are mixed in a single reaction vessel. For example, in a protein assay, the mixing of analytes (proteins) and the detection cocktail (labeled antibodies) can result in unintended secondary cross-reactions or interference that distort the measurements and severely compromise data quality. This biological cross reactivity can be mitigated by attempting to design the assay with components that do not negatively react; however, this becomes increasingly impractical and difficult (due to the high number of variables introduced) as the multiplex level increases. Moreover, even for sets of antibodies in the assay with components that do not negatively react, the multiplexed result is still typically relative to the performance of any one of the individual components, due to the application of a common assay buffer across all of the antibodies, which is typically not the optimal buffer with respect to pH, salinity, etc for each of the antibodies.


SUMMARY OF THE INVENTION

The present invention provides a new and unique method and apparatus for performing a chemical, biochemical, or biological assay on a sample, including a biological assay, e.g., on a patient sample, such as serum, plasma, cerebrospinal fluid, urine, blood, etc.


According to some embodiments of the present invention, the apparatus may take the form of an assay device or apparatus comprising: a microfluidic assay cartridge or device that contains at least one sample inlet well configured to receive a sample; and a microfluidic sub-unit associated with the microfluidic assay cartridge and comprising microfluidic channels, micro-valves and at least one separate and fluidicly isolated isolation channel, and at least one hollow element, e.g. including at least one hollow glass cylinder, tube or particle. The at least one hollow element may be functionalized with a capture moiety or molecules so as to form at least one reaction vessel. The microfluidic channels and micro-valves may be configured to respond to signaling containing information about performing the assay and to controllably receive the sample and at least one reagent in the at least one reaction vessel, and to provide from the at least one reaction vessel light containing information about the assay performed on the sample inside the at least one reaction vessel as a result of said at least one reagent.


By way of example, the microfluidic channels and micro-valves may also be configured to respond to the signaling containing information about performing the assay and to introduce into the at least one reaction vessel some combination of the following:

    • assay reagents, including a plurality of reagents, such as labeled antibodies,
    • reagents, including an enzymatic substrate, for producing an emitted light signal, and
    • introduce a wash solution to remove any non-specifically bound proteins or antibodies and/or hydrate dry reagents with a buffer;


where the at least one reaction vessel may be configured to allow chemical reactions to take place for performing the assay, and to provide emitted light containing information about the assay performed to be interrogated, based at least partly on the signalling received.


According to some embodiments, the present invention may comprise one or more of the following features: The microfluidic sub-unit may be configured to contain on-board the assay reagents, including the plurality of reagents, such as labeled antibodies, to contain on-board the reagents such as an enzymatic substrate for producing the emitted light signal, and/or on-board the wash solution to remove any non-specifically bound proteins or antibodies. These microfluidic sub units may also be configured such that the on-board reagents, such as those defined above, are contained in a dehydrated form, and are rehydrated by control signals to the microfluidic system that introduces buffer fluids to the said dehydrated reagents. Embodiments are also envisioned in which the assay reagents, the enzymatic substrate or wash solution are not contained on-board, but instead form part of another device, apparatus or equipment and provided to the assay device or apparatus. The apparatus may be configured with at least one common on-board waste receptacle or individual on-board waste receptacles that are configured to capture the wash solution, along with non-specifically bound proteins or antibodies. The microfluidic assay cartridge may be configured to be disposable. The apparatus may comprise a detection system configured to respond to the emitted light signal provided from at least one reaction vessel, and provide a signal containing information about the assay performed in relation to the at least one reaction vessel. The apparatus may comprise a controller configured to execute a computer program code and to provide the signaling to the microfluidic channels and micro-valves in order to perform the assay. Each of the series of microfluidic channels may be configured to correspond to a respective one of the at least one sample inlet well. Embodiments for some assays are also envisioned in which the wash is optional, and only the assay reagents and the enzymatic substrate are introduced, but not the wash. The at least one reaction vessel may be contained in a channel that may be configured to conduct independent assays, where the channel may be understood to be separate and fluidicly-isolated from other channels so as to substantially eliminate cross reactivity between the assays performed in the respective channels. The at least one reaction vessel contained in each isolation channel may be functionalized with the same capture moiety or capture molecules; or the at least one reaction vessel contained in each isolation channel may be each functionalized with a different capture moiety or capture molecules; or some combination thereof. The at least one hollow element may be configured as a honeycomb with multiple axial cavities or chambers. The at least one reagent may comprises a plurality of reagents.


According to some embodiments of the present invention, the apparatus may take the form of a controller that may be configured to control the performance of an assay by an assay device comprising a microfluidic assay cartridge that contains at least one sample inlet well configured to receive a sample; and a microfluidic sub-unit associated with the microfluidic assay cartridge and comprising microfluidic channels, micro-valves and at least one hollow element, the at least one hollow element being functionalized with a capture moiety or molecules so as to form at least one reaction vessel.


In this embodiment, the controller may comprise:


at least one processor and at least one memory device, including computer program code; the at least one memory device and the computer program code may be configured, with the at least one processor, to cause the controller at least to provide signalling containing information about performing the biological assay to the microfluidic channels and micro-valves, where the microfluidic channels and micro-valves are configured to respond to the signaling, to direct the sample from the at least one sample inlet well to the at least one reaction vessel, and to introduce into the at least one reaction vessel at least one reagent, so as to provide from the at least one reaction vessel light containing information about the assay performed on the sample inside the at least one reaction vessel as a result of the at least one reagent.


According to some embodiments, the present invention may also take the form of a method for performing the assay process using a new and unique separation technique consistent with that set forth above. The method may be implemented by providing the means set forth above for automatically separating components where negative cross reactions may occur, and by employing the microfluidic assay cartridge or device that will automate some of the manual steps typically associated with these types of tests. The separation technique set forth herein for performing the assay process will substantially minimize the need to design around cross reactivity. By way of example, the method may comprise some combination of the following:

    • functionalizing at least one hollow element by chemically cross-linking or passively adhering a capture antibody specific for a target analyte of interest onto the surface of the hollow element;
    • introducing a precise volume of a sample, which may contain a patient sample, including serum, plasma, cerebrospinal fluid, urine, blood, etc., by flowing the sample into a channel containing at least one reaction vessel, including either by positive or negative pressure, during which time the target analyte of interest is retained by virtue of specific binding to the capture antibody coated onto the surface of the at least one reaction vessel,
    • rinsing the reaction vessel with a buffer solution to wash away the unbound target analytes (e.g., protein);
    • either flowing a second antibody, referred to as a detection antibody based at least partly on the fact that the detection antibody is coupled to a fluorescent tag (conjugate) capable of emitting a light signal, whereupon the detection antibody binds to the target analyte retained on the surface of the at least one reaction vessel via the capture antibody, or alternatively flowing a second antibody without a fluorescent conjugate, rinsing the reaction vessel with a buffer to wash away unbound detection antibody, and then adding a fluorescent conjugate in a subsequent step;
    • rinsing the reaction vessel with a buffer solution to remove any unbound fluorescent conjugate,
    • irradiating a fluorescent chemical tag with an appropriate excitation wavelength onto the reaction vessel;
    • detecting an amount of fluorescent light emitted by the tagged detection antibody as a result of irradiating; and
    • quantifying an amount of the target analyte captured by the amount of fluorescent light emitted by the tagged detection antibody as a result of irradiating the fluorescent chemical tag with the appropriate excitation wavelength onto the reaction vessel, where the amount of analyte on the surface of reaction vessel will be proportional to the amount of light emitted by the fluorescently labeled detection antibody, and hence is directly proportional to the amount of analyte within the patient sample.


According to some embodiments, the present invention may also take the form of an apparatus consistent with that described above, but where the microfluidic channels are configured to respond to a control impulse containing information about performing the assay and to receive the sample and at least one reagent in the reaction vessel. By way of example, the control impulse may take the form of at least one control signal that causes pneumatic control lines to open or close micro-valves arranged in relation to the microchannel that causes the sample and the at least one reagent to flow into the at least one reaction vessel in order to perform the assay; or alternatively that causes a device arranged in relation to the microchannel to provide positive or negative pressure in the microchannel that causes the sample and the at least one reagent to flow into the at least one reaction vessel in order to perform the assay.


Embodiments are also envisioned within the spirit of the present invention in which, instead of using at least one hollow element having a capture moiety or molecules, one may use encoded or non-encoded microparticles having an outside surface functionalized, e.g. by coating, with the capture moiety or molecules, consistent with that disclosed in Ser. No. 12/945,459, filed 12 Nov. 2010, which is hereby incorporated by reference in its entirety.


Advantages

The present invention employs a novel reaction vessel that, in and of itself, enables very low cost manufacturing, fast reaction time, low sample volume, high sensitivity, and large dynamic range. The novel hollow reaction vessel may take the form of the at least one hollow element that has been functionalized with the capture moiety or capture molecules.


Advantages of embodiments of the present invention include substantially minimizing the need to design around cross reactivity by providing a means for automatically separating components where negative cross reactions occur. Additionally, this assay device will improve ease of use by employing a disposable microfluidic assay cartridge that will automate some of the manual steps typically associated with these types of tests. This assay device will optimize buffer conditions to produce independently optimized assays. The optimized buffer conditions may include optimizing in relation to the pH, salinity or both. This assay device will also allow samples to be independently diluted with buffer solution with respect to each channel.


It is the purpose of the present invention to deliver an apparatus or a method that provides multi-sample, multiplex assays with data quality that is significantly improved over current methods while at the same time providing greater ease of use.





BRIEF DESCRIPTION OF THE DRAWING

The drawing, which are not necessarily drawn to scale, includes the following Figures:



FIG. 1 includes the following: FIGS. 1(a) which shows a microfluidic assay cartridge or device according to some embodiments of the present invention; FIG. 1(b) which shows a microfluidic sub-unit corresponding to at least one sample inlet well of the microfluidic cartridge shown in FIG. 1(a) according to some embodiments of the present invention; and FIG. 1(c) which shows a flowchart having steps for performing a biological assay, e.g., using the combination of the microfluidic assay cartridge or device shown in FIG. 1(a) and the microfluidic sub-unit shown in FIG. 1(b).



FIG. 2 is a diagram showing detail of an isolation channel with embedded reaction vessel that forms part of the microfluidic sub-unit shown in FIG. 1(b) according to some embodiments of the present invention.



FIG. 3 shows channel geometry of an isolation channel that can form part of the microfluidic sub-unit shown in FIG. 1(b) according to some embodiments of the present invention, including FIG. 3a showing a magnified photograph of examples of square channels, a partially filled channel and a pneumatic channel; FIG. 3b showing an example of a channel having no fill; FIG. 3c showing an example of a channel having 20% fill; FIG. 3d showing an example of a channel having 60% fill; FIG. 3e(1) showing a diagram of a hollow element fit within walls of the isolation channel looking from the top; FIG. 3e(2) showing a diagram of the hollow element fit within walls of the isolation channel shown in FIG. 3e(1) looking from the end along the longitudinal axis of the hollow element; FIG. 3f(1) showing a diagram of a hollow element fit within walls of the isolation channel with fill material looking from the top; FIG. 3f(2) showing a diagram of the hollow element fit within walls of the isolation channel with fill shown in FIG. 3f(1) looking from the end along the longitudinal axis of the hollow element; and FIG. 3g is an epoxy down select matrix showing rows of epoxy in relation to columns of parameters, including indication of type, viscosity, dispensable, fluorescence, cure method, comment and acceptable.



FIG. 4 shows a magnified photograph of an example of a pneumatically actuated pump having valves, a piston, a fluidic channel and pneumatic lines according to some embodiments of the present invention.



FIG. 5 shows an example of pump operation in relation to valves and a piston arranged between an inlet reservoir and a destination according to some embodiments of the present invention.



FIG. 6
a(1) shows an example of a 4-plex architecture with independent pump control and individual waste reservoirs according to some embodiments of the present invention; FIG. 6a(2) shows an example of Normally Closed (NC) (vacuum actuated) states for buffer pumping (1 complete cycle) for the 4-plex architecture shown in FIG. 6a(1) according to some embodiments of the present invention; FIG. 6b shows an example of a 4-plex architecture with independent pump control and a common waste reservoir according to some embodiments of the present invention; FIG. 6c shows an example of a 4-plex architecture with a common pump control, a common waste reservoir and a by-pass channel according to some embodiments of the present invention; and FIG. 6d shows an example of a 4-plex architecture with a common pump control, a common waste reservoir, a by-pass channel and an antibody rehydration channel according to some embodiments of the present invention.



FIG. 7 includes the following: FIG. 7a is a photograph of a microfluidic chip according to some embodiments of the present invention; FIG. 7b shows an expanded and magnified view of three reaction vessels embedded in an isolation channel of the microfluidic chip shown in FIG. 7a according to some embodiments of the present invention; FIG. 7c(1) is a graph of counts per second versus time of a real time signal evolution due to binding of a secondary Ab (IL6) to a captured antigen inside three embedded reaction vessels; FIG. 7c(2) shows fluorescence images of three embedded reaction vessels after 15 minutes; and FIG. 7d shows a graph of mean fluorescent intensity per second versus IL6 in picograms/millilitre related to dose response curves for an IL6 sandwich assay performed on reaction vessels in batch mode.



FIG. 8 includes the following: FIG. 8a which is a view of a hollow element having a hex-shaped honeycomb configuration with multiple reaction cavities or chambers according to some embodiments of the present invention, and FIG. 8b is a view of a hollow element having a circularly-shaped honeycomb configuration with multiple reaction cavities or chambers according to some embodiments of the present invention.





DETAILED DESCRIPTION OF THE INVENTION
FIG. 1

In FIG. 1, the present invention takes the form of an apparatus generally indicated as 50 shown in FIG. 1 that may include a microfluidic assay cartridge or device (1) which will contain at least one sample inlet well (2), as shown in FIG. 1(a). Each sample inlet well (2) will feed, e.g. based at least partly on some control logic, into a respective microfluidic sub-unit (3) embedded within the microfluidic assay cartridge or device (1), as shown in FIGS. 1 and 1(b). In FIG. 1(a), the microfluidic assay cartridge or device (1) is shown by way of example as having a plurality of sample inlet wells (2) in the form of 4 by 6 matrix, totally 24 sample inlet wells. The scope of the invention is not intended to be limited to the number of sample inlet wells (2), and is intended to include any number of sample inlet wells (2) ranging from 1 sample inlet well (2) to N sample inlet wells (2). The microfluidic assay cartridge or device (1) and/or microfluidic sub-unit (3) may be constructed and/or made from a material so as to be disposable or reusable, and the scope of the invention is not intended to be limited to the type or kind of material used to construct or make the microfluidic assay cartridge or device (1) and/or microfluidic sub-unit (3) either now known or later developed in the future.


The microfluidic sub-unit (3) contains a series of microfluidic channels and micro-valves (4) that direct a sample, including a patient sample, such as serum, plasma, cerebrospinal fluid, urine, blood, etc., from the at least one sample inlet well (2) to separate and fluidicly-isolated channels (5) that contain one or more reaction vessels (19), which have been functionalized with a capture moiety or capture molecules such as antibodies, antigens, or oligomers, as shown in FIG. 1(b). In FIG. 1b, each isolation channel (5) is shown having four reaction vessels (19) for a combine total of 16 reaction vessels is channels C1, C2, C3, C4, although the scope of the invention is not intended to be limited to any particular number of reaction vessels (19) in each isolation channel (5), consistent with that described herein. Assay reagents (7) including reagents R1, R2, R3, R4, such as labeled antibodies, will be introduced into the separate isolation channels (5) via the microfluidic channels (8) and micro-valves (4). Additionally, the microfluidic channels (8) and micro-valves (9) are provided to introduce reagents such as an enzymatic substrate (10) for producing an emitted light signal and a wash solution (11) to remove any non-specifically bound proteins or antibodies. The wash solution (11), along with non-specifically bound proteins or antibodies, is captured in an on-board waste receptacle (12). Chemical reactions taking place in the reaction vessels (19) are interrogated by a detection system (13). (It is noted that the addition of the enzymatic substrate (10) forms part of one technique of performing the biological assay, which may be contrasted to an alternative technique described below in relation to FIG. 6. See also the alternative embodiments described in relation to FIG. 1(c).)



FIG. 2 shows in further detail as generally indicated by (6) the isolation channel (5) and reaction vessel (19) embedded therein which has been designed such that it can tolerate a large confocal region or zone (18), and as a consequence may not require high resolution optics to avoid background fluorescence. In addition, the isolation channel and reaction vessel have been designed to enable very low cost manufacturing, and may include leveraging existing fiber optic and injection molded plastic technology. This low cost is achieved while at the same time providing very good optical qualities, increased sensitivity, decreased reaction time, large dynamic range, and low sample volume requirements.


The biological reactions take place inside at least one hollow element (14) which has been functionalized with a capture moiety or molecules (15), so as to form the reaction vessel (19). By way of example, the at least one hollow element (14) may be configured or fabricated by drawing glass tubing with an outer diameter and an inner diameter, and cutting or dicing it, e.g., with a dicing saw. The at least one hollow element (14) may also be configured or fabricated by etching out the core of commercially available high NA fused silica optical fibers or rods, which provide extremely high optical quality at a very low cost. The present invention is described by way of example with the at least one hollow element (14) being made of glass; however, the scope of the invention is intended to include making the at least one hollow element (14) from other types or kind of material either now known or later developed in the future, including other types or kinds of non-glass materials. The at least one hollow element (14) may be suspended in a housing (16) with a significant amount of air space (17) surrounding the outside diameter of the at least one hollow element (14). This air space (17) provides the large confocal zone (18) by providing an area that is free from any introduced background fluorescence. The at least one hollow element (14) may be installed with a press or friction fit into and received by walls of the housing (16), which is described in further detail below, that will direct the sample through the inside diameter of the at least one hollow element (14), and prevent the sample from entering the air space (17) surrounding the at least one hollow element (14). The at least one hollow element (14) may be configured or designed with a cavity or chamber having a very small inside diameter (e.g., approximately 10 μm inner diameter (ID)) and a length-to-I.D. aspect ratio of, e.g., approximately 20:1 (approximately 200 μm L). This configuration provides the reaction vessel (19) with a very high surface area-to-volume ratio, which in-turn drives fast reaction kinetics. In addition, the effect of the sample being forced through a very low volume reaction vessel increases the probability of a binding event because a higher proportion of the sample comes in contact with the functionalized surface of the hollow element, thereby increasing sensitivity. In FIG. 2, the isolation channel and reaction vessel detail is understood to take the form of at least one hollow element (14) that is functionalized with the capture moiety or molecules (15), and is arranged in and coupled to the housing (16) in an isolation channel (5) as shown.


As shown in FIG. 2, light Lin from a light source (20) can be passed through a dichroic beam splitter (22), a lens (24) and the air space (17) to the large confocal region or zone (18); and light Lout can be passed back through the air space (17), the lens (24), the dichroic beam splitter (22), a lens (26) to the detector (13).


In an alternate embodiment of this invention, a plurality of hollow elements (14) of decreasing inside diameters can be functionalized and placed in-line to address varying analyte densities, prevent oversaturation, and extend the dynamic range of the systems analysis capabilities. Alternatively, a plurality of hollow elements of the same diameter that have been functionalized with different loading densities of the capture moiety or molecules can be placed in-line to address varying analyte densities, prevent over saturation, and extend the dynamic range. It is also envisioned that combinations of the above configuration can be employed to achieve optimized results.


The scope of the invention is not intended to be limited to any particular type or kind of sample that forms part of the assay process, and is intended to include samples of substance both now known and later developed in the future.


The at Least One Sample Inlet Well (2)

In FIG. 1, each of the at least one sample inlet well (2) of the disposable microfluidic assay cartridge or device (1) corresponds to a respective microfluidic sub-unit (3) embedded within the disposable microfluidic assay cartridge (1). However, the scope of the invention is also intended to include embodiments in which multiple sample inlet wells (2) of the disposable microfluidic assay cartridge or device (1) are configured to correspond to a respective microfluidic sub-unit (3) via, e.g., a manifold device (not shown).


The Assay Reagents and Channel

In FIG. 1, each assay reagent R1, R2, R3, R4 may correspond to, feed into and be assigned to a respective isolation channel C1, C2, C3, C4. However, the scope of the invention is also intended to include embodiments in which each assay reagent R1, R2, R3, R4 feeds into multiple channels C1, C2, C3, C4.


The Detection System (13)

In FIG. 1, each of the microfluidic sub-units (3) embedded within the disposable microfluidic assay cartridge (1) has a respective detection system (13). However, the scope of the invention is also intended to include embodiments in which multiple microfluidic sub-unit (3) are configured to correspond to a respective detection system (13). By way of example, a first column or group of four microfluidic sub-unit (3) may correspond to a first detection system (13); a second column or group of four microfluidic sub-unit (3) may correspond to a second detection system (13); . . . ; and a sixth column or group of four microfluidic sub-unit (3) may correspond to a sixth detection system (13). Alternatively, by way of example, a first row or group of six microfluidic sub-unit (3) may correspond to a first detection system (13); a second row or group of six microfluidic sub-unit (3) may correspond to a second detection system (13); . . . ; and a fourth row or group of six microfluidic sub-unit (3) may correspond to a fourth detection system (13). The scope of the invention is also intended to include embodiments in which N microfluidic sub-unit (3), where N, e.g., equals 24 corresponding to that shown in FIG. 1, are configured to correspond to a single detection system (13). The scope of the invention is also intended to include embodiments in which the detection system (13) is on-board and forms part of microfluidic sub-unit (3), as well as embodiments where the detection system (13) is not on-board but forms part of another device, apparatus or equipment either now known or later developed in the future.


The Controller (140)

The apparatus may also include a controller (140) for implementing the functionality associated with the assay performed by the microfluidic sub-unit (3) embedded within the disposable microfluidic assay cartridge or device (1). The controller (140) may be configured to execute a computer program code and to provide the signaling along signal paths, e.g., S0, S1, S2, S3, S4, S5, S6, . . . , S10 to each microfluidic channel (8) and/or micro-valves (4, 9) in order to perform the assay. In operation, the controller (140) may be configured to execute the computer program code and to exchange signaling along signal path S7 with the detection system (13), including receiving a detection system signal containing information about the reactions taking place in the reaction vessels (19) being interrogated by the detection system (13). The controller (140) may also be configured to receive an input signal(s) along signal path Sin, and to provide an output signal(s) along signal path Sout. By way of example, the output signal along signal path Sout may contain either the raw detection system signal containing information about the reactions taking place in the reaction vessels (19) being interrogated by the detection system (13), or a processed detection system signal containing information about the reactions taking place in the reaction vessels (19) being interrogated by the detection system (13). By way of example, the input signal along signal path Sin may contain information to control or modify the functionality of the controller (140), including a signal requesting the provisioning of the output signal along signal path Sout. The scope of the invention is not intended to be limited to the type or kind of information being provided to or received by the controller (140) via the input signal along signal path Sin or the type or kind of information being provided from the controller (140) via the output signal along signal path Sout either now known or later developed in the future. Further, by way of example, the controller (140) may be implemented using hardware, software, firmware, or a combination thereof. In a typical software implementation, the controller (140) would include one or more microprocessor-based architectures having a processor or microprocessor, memory such as a random access memory (RAM) and/or a read only memory (ROM), input/output devices and control, data and address buses connecting the same. A person skilled in the art would be able to program such a microcontroller or microprocessor-based implementation with the computer program code to perform the functionality described herein without undue experimentation. The scope of the invention is not intended to be limited to any particular microprocessor-based architecture implementation using technology either now known or later developed in the future.


Embodiments are envisioned in which the controller (140) either is on-board and forms part of the apparatus (50), or is not on-board but forms part of another apparatus, device, system or equipment that cooperates with the apparatus (50) in relation to implementing the assay process with the microfluidic technology disclosed herein.


In FIG. 1(b), the microfluidic sub-unit (3) is shown, by way of example, with micro-valves (4, 9) arranged in relation to the substrate (10), the wash (11) and the assay reagents (7) to control the introduction of the assay reagents to the isolation channels (5) in response to the signalling along signalling paths S0, S1, S2, S3, S4, S5, S6, . . . , S10 using steps 3-8 described below and set forth in the flowchart shown in FIG. 1(c). Embodiments are also envisioned in which the micro-valves (4) provide information back to the controller (140) via corresponding signalling along signalling paths S0, S1, S2, S3, S4, S5, S6, . . . , S10, for controlling the introduction of the assay reagents (7), the substrate (10) and the wash (11). Embodiments are also envisioned in which other micro-valves are arranged at other points in relation to each microfluidic channel (8), e.g. such as micro-valves (4a) in FIG. 1(b) arranged in relation to the interface between each microfluidic channel (8) and the at least one sample inlet well (2) for controlling the provisioning of the sample into the microfluidic channel (8) with signalling along signal path S0. Embodiments are also envisioned in which other micro-valves are arranged in relation to the isolation channels (5), including at either or both ends, so as to control the passage of the solution, reagents or buffer through the isolation channels (5). The scope of the invention is not intended to be limited to the number, position, or arrangements of the micro-valves, like (4) or (4a) or (9).


By way of example, the micro-valves (4, 4a, 9), isolation channels (5), detection system (13), along with other components or devices shown and described herein in relation to FIG. 1, are either known in the art, or can be implemented to perform the desired functionality without undue experimentation by one skilled in the art; and the scope of the invention is not intended to be limited to any particular type or kind thereof either now known or later developed in the future. Furthermore, based of the disclosure herein, one skilled in the art could implement the apparatus 50 shown in FIG. 1, including the microfluidic assay cartridge (1) shown in FIG. 1(a) and the microfluidic sub-unit (3) embedded therein shown in FIG. 1(b), to perform the desired functionality without undue experimentation.


The present invention is described by way of using micro-valves configured to control the flow of one or more of the sample, the assay reagents (7), the substrate (10) and the wash (13) into the at least one separate and fluidicly-isolated isolation channels (5). However, the scope of the invention is intended to include using other types or kind of techniques either now known or later developed in the future to control the flow of one or more of the sample, the assay reagents (7), the substrate (10) and the wash (13) into the at least one separate and fluidicly-isolated isolation channels (5), e.g., such as by using a configuration to provide positive pressure to push and cause the flow of one or more of the sample, the assay reagents (7), the substrate (10) and the wash (13) into the at least one separate and fluidicly-isolated isolation channels (5), or such as by using a configuration to provide negative pressure (e.g. a vacuum) to pull (or draw) and cause the flow of one or more of the sample, the assay reagents (7), the substrate (10) and the wash (13) into the at least one separate and fluidicly-isolated isolation channels (5), or such as by using some combination of pushing and/or pulling to cause the flow of one or more of the sample, the assay reagents (7), the substrate (10) and the wash (13) into the at least one separate and fluidicly-isolated isolation channels (5). The configuration to provide positive pressure may be configured on the upper end (as shown in FIG. 1(b)) of the at least one separate and fluidicly-isolated isolation channels (5) in relation to the assay reagents (7) and channels C1, C2, C3, C4, while the configuration to provide negative pressure may be configured on the lower end (as shown in FIG. 1(b)) of the at least one separate and fluidicly-isolated isolation channel (5) in relation to the waste (12) and channels C1, C2, C3, C4.


Immunoassay Process for Sandwich ELISAs

By way of example, the process of conducting an immunoassay in a cartridge according to the present invention using a sandwich enzyme-linked immunosorbent assay (ELISA) may entail some combination of the following:


Step 1: A capture antibody specific for the target analyte of interest is chemically cross-linked onto the surface of the hollow element (14) in FIG. 2 so as to form the reaction vessel (19)).


Step 2: The reaction vessel (19) once placed into the isolation channel (5) is then ready to receive the patient sample (serum, plasma, cerebrospinal fluid, urine, blood, etc).


Step 3: A precise volume of the patient sample is then introduced by flowing the material into the reaction vessel (19), either, e.g., by positive or negative pressure, during which time the target analyte of interest is retained by virtue of specific binding to the capture antibody coated onto the interior surface of the reaction vessel (19).


Step 4: The reaction vessel (19) is then rinsed with a buffer to wash away the unbound protein.


Step 5: The second antibody, referred to as a detection antibody since it is coupled to a fluorescent tag capable of emitting a light signal, is then is flowed into the reaction vessel (19) whereupon it binds to the target analyte retained on the interior surface via the capture antibody.


Step 5a: An alternative embodiment of this process may be to use a second antibody without a fluorescent conjugate, and then to add the fluorescent conjugate in a subsequent step. Note that this may also include an additional rinse step prior to adding the fluorescent conjugate.


Step 6: The reaction vessel (19) is then rinsed again with a buffer to remove unbound protein, and the excess fluorescent tag.


Step 7: The amount of the target analyte captured is then quantified by the amount of fluorescent light emitted by the detection antibody as a result of irradiating the fluorescent chemical tag with the appropriate excitation wavelength onto the reaction vessel (19).


Step 8: The amount of analyte within the reaction vessel (19) is proportional to the amount of light emitted by the detection antibody fluorescent tag, and hence is directly proportional to the amount of analyte within the patient sample.


The controller (140) shown in FIG. 1(b) may be implemented and configured to provide the signalling to perform the biological assay using, e.g., steps 3-8 set forth above.


The scope of the invention is described by way of example using the sandwich ELISA biological assay technique. However, the scope of the invention is not intended to be limited to using the sandwich ELISA biological assay technique, e.g., embodiments are also envisioned using other types or kind of biological assay techniques either now known or later developed in the future, including an “indirect” ELISA, a competitive ELISA, a reverse ELISA, as well as other non-ELISA techniques.


FIG. 3: Channel Geometry

By way of example, FIG. 3 shows channel geometry of an isolation channel (5) that may form part of the microfluidic sub-unit (3) shown in FIG. 1(b) according to some embodiments of the present invention.



FIG. 3
a shows examples of a square channel, a partially filled channel and a pneumatic channel.


In some embodiments, the channel may be partially filled with Polydimethylsiloxane (PDMS) fillet to form a conformal surface for a membrane seal, configured to engage an outer surface of the hollow element (14). See FIG. 3c. By way of example, partially filling a channel with PDMS could be used to engage the outer surface of the hollow element so as to reduce the free volume around the cylinder.

    • If no fill (square channel) is used, then the channel cannot be closed by the membrane, which may take the form of a very thin layer of PDMS. See FIG. 3b, where air pressure, e.g. from the pneumatic control of a microvalve, can partially push the membrane down into the channel, but can still result in a fluidic leak path, as shown.
    • Alternatively, the use of a higher degree of fill reduces strain on the membrane, lowers required air pressure, but creates channel occlusion.


PDMS is a material that belongs to a group of polymeric organosilicon compounds that are commonly referred to as silicones. PDMS material doesn't fluoresce which is important in processing the light signal received back from the reaction vessel (19).



FIGS. 3
e(1) and 3e(2) show the hollow element (14) fit within walls W1, W2 of the housing (16) that forms part of the isolation channel (5). See FIG. 1b and FIG. 3b. The hollow element (14) is retained in channel by friction fit with walls W1, W2. Free space exists between outside of the hollow element (14) and channel walls W1, W2.



FIGS. 3
f(1) and 3(f)2 show the hollow element (14) fit within walls W1, W2 of the housing (16) that forms part of the isolation channel (5) with fill. See FIG. 1b and FIGS. 3b and 3c. The hollow element (14) is retained in channel (5) by a fill material that may take the form of an epoxy-like material, silicone rubber, etc., placed in channel floor prior to insertion of the hollow element fit (14). Alternatively, the isolation channel (5) may be completely filled around the hollow element fit (14) to completely block flow around particle.


In FIG. 3g, an epoxy down select matrix shows rows of epoxy in relation to columns of parameters, including indication of type, viscosity, dispensable, background fluorescence, cure method, comment and acceptable. The PDMS material includes the Sylgard 184, Sylgard 186 and the Nusil materials listed.


FIG. 4: Pneumatically Activated Pump


FIG. 4 shows, by way of example, one prototype of a pneumatically actuated pump having valves, a piston, a fluidic channel and pneumatic lines according to some embodiments of the present invention. In FIG. 4, the piston displacement for this prototype is about 200 nl (nanoliters), which may be far more than what is likely to be required.


FIG. 5: Pump Operation


FIG. 5 shows an example of pump operation in relation to valves and a piston arranged between an inlet reservoir and a destination according to some embodiments of the present invention. In FIG. 5, the pump operation includes pumping that is accomplished by combining 2 pneumatically actuated valves V1, V2 with at least one pneumatically actuated piston located between the two valves V1, V2. The purpose of the piston is simply to displace fluid, either by pulling it in from a reservoir or pushing it in the direction of the flow. The valves V1, V2, which buttress the piston, ensure unidirectional flow. Full operation is accomplished by actuating the 3 components in a particular sequence. For example, to move fluid from the inlet reservoir to the destination, as shown in FIG. 5, a valve sequence may entail the following: close the valve V1, compress the Piston, close the valve V2, open the valve V1, decompress the piston, close valve V1, open the valve V2 and compress the Piston. In a larger network of channels and valves, the flow can be generated by combining any set of 2 valves and a piston. In other words, valves can be used as simple open and close valves or they can be incorporated into a pump as described here.


FIG. 6: Various 4-plex Architectures

By way of example, FIGS. 6a(1), 6b, 6c and 6d show various 4-plex architectures for performing an assay according to some embodiments of the present invention. For instance, FIG. 6a(1) shows a 4-plex architecture with independent pump control and individual waste reservoirs, and FIG. 6a(2) shows the NC (vac actuated) states for buffer pumping (1 complete cycle) for the 4-plex architecture shown in FIG. 6a(1), according to some embodiments of the present invention. In the fluidic network shown in FIG. 6a(1), there are a number of fluidic channels C1, C2, C3, C4 with pneumatically actuated valves V located at various locations along the channels. The valves V connected to one another are actuated simultaneously. Valve set 3 is pistons and valve set 4 is the outlet valves and these are used for all of the pumping operations regardless of the fluid source. Depending on which fluid is being pumped (sample, buffer or detection Ab) the particular valve used in combination to provide pumping may be 1, 8 or 7 respectively. FIG. 6a(2) shown the state diagram for one complete sequence required to pump buffer from the source through the main channels and out the their respective waste reservoirs.


By way of example, FIG. 6b shows a 4-plex architecture with independent pump control similar to the 4-plex in FIG. 6a(1), but with a common waste reservoir W feeding from the isolation channels (5).


By way of example, FIG. 6c shows an example of a 4-plex architecture with a common pump control and a common waste reservoir similar to the 4-plex in FIG. 6b, but with a by-pass channel feeding from the microchannel to the common waste reservoir.


By way of example, FIG. 6d shows an example of a 4-plex architecture with a common pump control, a common waste reservoir and a by-pass channel similar to the 4-plex in FIG. 6c, but with an antibody rehydration channel.


Method for Performing an Assay Using a Separation Technique

The present invention may also take the form of a method for performing the assay process using a new and unique separation technique consistent with that set forth above. The method may be implemented by providing the means set forth above for automatically separating components where negative cross reactions occur, and by employing the disposable microfluidic assay cartridge that will automate some of the manual steps typically associated with these types of tests. The separation technique set forth herein for performing the assay process will eliminate the need to design around cross reactivity.


By way of example, the method for performing an assay may be implemented using the microfluidic technology in FIG. 1 as follows:


providing a microfluidic assay cartridge (1) that contains at least one sample inlet well (2) configured to receive a sample; and a microfluidic sub-unit (3) associated with the microfluidic assay cartridge (1) and configured to controllably receive the sample from the microfluidic assay cartridge (1); the microfluidic sub-unit (3) comprising microfluidic channels (8), micro-valves (4, 4a, 9), and at least one separate and fluidicly isolated isolation channel (5), and at least one reaction vessel (19), the reaction vessel (19)) comprising at least one hollow element (14) which has been functionalized with a capture moiety or capture molecules (15);


responding to signaling containing information about performing the assay with the microfluidic channels (8) and micro-valves (4, 9), and controllably receiving the sample and the at least one reagent in the at least one reaction vessel (19), so as to provide light containing information about the assay performed on the sample inside the at least one hollow element (14) as a result of the at least one reagent.


The method may also comprise responding to the signaling containing information about performing the assay with the microfluidic channels (8) and micro-valves (4, 9) and introducing into the reaction vessel (19) the following:

    • assay reagents (7), including a plurality of reagents (R1, R2, R3, R4), such as labeled antibodies,
    • reagents, including an enzymatic substrate (10), for producing an emitted signal, and
    • a wash solution (11) to remove any non-specifically bound proteins or antibodies; and


allowing with the at least one reaction vessel (19) chemical reactions to take place for performing the assay, and providing the emitted light containing information about the assay performed to be interrogated, e.g. by the detection system (13).


Further, by way of example, the method for performing an assay may also be implemented using the microfluidic technology in FIG. 2.


Furthermore, by way of example, the method for performing a biological assay may also be implemented using the steps set forth above, including those set forth in relation to FIG. 1(c).


The Assay

Many different types and kinds of assays may be performed using the present invention, including a chemical assay or a biological assay.


For example, a singular and multiplexed biological assay may be performed by using at least one functionalized hollow glass cylinder, tube or particle (14) in different isolation channel (5), by using multiple functionalized hollow glass cylinders, tubes or particles (14) in the same isolation channel (5), or by using multiple functionalized hollow glass cylinders, tubes or particles (14) in multiple isolation channels (5).


Further, a multiplexed biological assay may be performed by using multiple reaction vessels, each with different concentrations of capture molecules, all located in a single isolation channel. For example, a first isolation channel C1 may include three reaction vessels, one with a low concentration of capture molecules immobilized on it, a second reaction vessel with a higher concentration of capture molecules immobilized on it, and third reaction vessel with an even higher concentration of capture molecules immobilized on it. A second isolation channel could include reaction vessels with the same range of capture concentrations or a completely different range of capture concentrations or a set of reaction vessels with all of the same reaction concentration. Further, a multiplexed biological assay may be performed by using multiple reaction vessels, each with different inner diameters, all located in the same isolation channel. For example, a first isolation channel C1 may include three reaction vessels, one with a small inside diameter and surface area, a second reaction vessel with a larger inside diameter and surface area, and third reaction vessel with an even larger inside diameter and surface area, so as to introduce different reaction kinetics. A second isolation channel C2 could contain the same set of reaction vessels with the same range of inner diameters or contain a completely different set of reaction vessels with a different range of inner diameters or with all of the same diameters.


Further still, a multiplexed biological assay may be performed by using positive and negative controls. For example, a first isolation channel C1 may include using a positive control, and a negative control while a second isolation channel C2 may also include using a positive and negative control that shouldn't react. Besides, biological assays with +/− controls may include using functionalized hollow glass cylinders, tubes or particles (14) having different antibodies, where the + control spikes and the − control does not react, but can be used, e.g., to gain information about background fluorescents.


Further still, a multiplexed biological assay may be performed by using different channels having different numbers of analytes, e.g., a first isolation channel C1 may include a first number of analytes (e.g. 1), a second isolation channel C2 may include a second number of analytes (e.g. 3), and a third isolation channel C3 may include a third number of analytes, . . . , an Nth isolation channel has an Nth number of analytes.


Further still, a multiplexed biological assay may be performed by using different isolation channels having different biological assays. For example, a first isolation channel C1 may include a first biological assay A, a second isolation channel C2 may include a second biological assay B, and a third isolation channel C3 may include a third biological assay A+B, so that channels can be looked at individually and together, which the channel B biological assay and the channel A+B biological assay can be used to provide further information about the channel A biological assay.


In summary, the present invention affords the possibility of a broad range of hybrid (or conventional) multiplex concepts, including (1) multiple reaction vessels in the same isolation channel, functionalized with different loading densities to extend the dynamic range; (2) multiple reaction vessels with different inner diameters, in the same isolation channel, to introduce different reaction kinetics; (3) multiple reaction vessels having positive and negative controlled reaction vessels in the same isolation channel; (4) multiple reaction vessels with different capture moieties in the same isolation channel, for the purpose of providing a multiplexed (conventional) reaction; and (5) multiple reaction vessels to conduct monoplex and multiplex reactions so that the results may be compared.


The scope of the invention is also intended to include other types or kinds of assays, including a chemical assay or a biological assay, either now known or later developed in the future.


FIG. 7

In FIGS. 7a and 7b, a microfluidic chip consisting of fluidic channels, including isolation with three embedded reaction vessels, pneumatic control lines and inlet/outlet ports, where the three reaction vessels are embedded in isolation channel. By way of example, the reaction vessels are about 500 microns long, have an outer diameter (OD)=about 150 um, and have an inner diameter (ID)=about 30 um.



FIGS. 7
c(1) and 7c(2) show the real-time signal evolution due to binding of secondary Ab (IL6) to previously captured antigen inside 3 embedded reaction vessels, and fluorescence images of three embedded reaction vessels taken 15 minutes after flowing detection Ab through the isolation channel and the embedded reaction vessel.



FIG. 7
d shows dose response curves for an IL6 sandwich assay performed on the reaction vessels in batch mode. Each data point represents a subset of reaction vessels, take from the same original batch of reaction vessels, but mixed with different IL6 antigen concentrations ranging from 0 pg/ml to 100,000 pg/ml. Clearly shown is the response to the changing concentration of antigen. This batch mode process would be used to both characterize a particular set of reaction vessels and verify the quality of the batch on the very inexpensive component.


Advantages of embedded reaction vessels include the following:


(1) Reaction vessels are made by dicing long strands of hollow glass tubing with the preferred outer and inner dimension into short sections of approximately 100-500 um long.


(2) Because the glass starting material is made with optical fiber manufacturing process, which have been highly optimized over the last 2 decades, and diced with precision diamond cutting machines, dimension control of the reaction vessels are quite excellent.


(3) Because the inside of the reaction vessel is functionalized in a batch process, meaning that up to 1000's of vessels at once are coated with the same solution of Ab, tight statistical control of the active binding moiety can be achieved.


(4) Large batches of reaction vessels means that stringent quality control and characterization of the active element of the biological assay can be performed at very low cost and with high statistical significance.


(5) The inside of the reaction vessels is protected by the outside surface which enables facile and robust techniques for picking up and placing the reaction vessels into the isolation channels without risk of damaging the fragile surface.


FIG. 8


FIG. 8 shows the hollow element may be configured as a honeycomb with multiple axial cavities or chambers that provides, when functionalized, a highly increased surface to volume ratio when compared to a reaction vessel having a single axial cavity or chamber affording the benefit of higher reaction kinetics and that also provides increased signal interrogation for the same effective volume.


The Microfluidic Technology

By way of example, the term “microfluidics” is generally understood to mean or deal with the behavior, precise control and manipulation of fluids that are geometrically constrained to a small, typically sub-millimeter, scale. In the present application, the microfluidic technology described herein is intended to include technology dimensioned in a range of about 20 micron to about 1000 microns, although the scope of the invention is not intended to be limited to any particular range.


The Scope Of The Invention

Embodiments shown and described in detail herein are provided by way of example only; and the scope of the invention is not intended to be limited to the particular configurations, dimensionalities, and/or design details of these parts or elements included herein. In other words, a person skilled in the art would appreciate that design changes to these embodiments may be made and such that the resulting embodiments would be different than the embodiments disclosed herein, but would still be within the overall spirit of the present invention.


It should be understood that, unless stated otherwise herein, any of the features, characteristics, alternatives or modifications described regarding a particular embodiment herein may also be applied, used, or incorporated with any other embodiment described herein. Also, the drawing herein are not drawn to scale.


Although the invention has been described and illustrated with respect to exemplary embodiments thereof, the foregoing and various other additions and omissions may be made therein and thereto without departing from the spirit and scope of the present invention.

Claims
  • 1. An apparatus for performing an assay, including a chemical biological or biochemical assay, on a sample comprising: a microfluidic assay cartridge or device that contains at least one sample inlet well configured to receive a sample;a microfluidic sub-unit associated with the microfluidic assay cartridge or device comprising microfluidic channels, micro-valves and at least one hollow element, the at least one hollow element being disposed within a channel and being functionalized on its inside surface with a capture moiety or molecules so as to form at least one reaction vessel;the microfluidic channels and micro-valves configured to respond to signaling containing information about performing the assay and to controllably receive the sample and at least one reagent through the at least one reaction vessel, and to provide from the at least one reaction vessel light containing information about the assay performed on the sample inside the at least one reaction vessel as a result of said at least one reagent;wherein the hollow element forming the reaction vessel is a section of long strands of hollow glass tubing of 100 to 500 microns in length, the reaction vessels having been functionalized on their inside surface in a batch process in which a plurality of the reaction vessels are coated at once with the same solution of the capture moiety;wherein free space exists between the outside of the hollow element forming the reaction vessel and the walls of the microfluidic channels; andwherein the assay cartridge contains the at least one hollow element within a channel having a piston associated with micro-valves forming a pump.
  • 2. An apparatus according to claim 1, wherein the microfluidic channels and micro-valves are configured to respond to the signaling containing information about performing the assay and to introduce into the at least one reaction vessel one or more of the following: assay reagents, including a plurality of assay reagents, including labeled antibodies, andreagents, including an enzymatic substrate, for producing an emitted signal, andthe at least one reaction vessel configured to allow reactions to take place for performing the assay.
  • 3. An apparatus according to claim 2, wherein the microfluidic channels and micro-valves are configured to respond to the signaling containing information about performing the assay and to introduce into the at least one reaction vessel a wash solution to remove any non-specifically bound proteins or antibodies.
  • 4. An apparatus according to claim 1, wherein the microfluidic sub-unit is configured to contain the assay reagents, including the at least one reagent, such as labeled antibodies; or the microfluidic sub-unit is configured to contain the reagents such as an enzymatic substrate for producing the emitted signal; or the microfluidic sub-unit is configured to contain the wash solution to remove any non-specifically bound proteins or antibodies, or some combination thereof.
  • 5. An apparatus according to claim 3, wherein the apparatus comprises an on-board waste receptacle that is configured to capture the wash solution, along with non-specifically bound proteins or antibodies.
  • 6. An apparatus according to claim 1, wherein the microfluidic assay cartridge is disposable.
  • 7. An apparatus according to claim 1, wherein the apparatus comprises a detection system configured to respond to the emitted signal, and provide a detection system signal containing information about the assay performed.
  • 8. An apparatus according to claim 1, wherein the apparatus comprises a controller configured to execute a computer program code and to provide the signaling to the microfluidic channels and micro-valves in order to perform the assay.
  • 9. An apparatus according to claim 1, wherein each of the plurality of microfluidic channels that comprise the microfluidic sub unit, corresponds to a respective one of the at least one sample inlet well, and wherein the microfluidic channels are fluidicly isolatable from each other.
  • 10. A microfluidic assay cartridge or device for performing an assay, including a chemical or biological assay, on a sample, comprising: at least one sample inlet well configured to receive a sample;microfluidic channels fluidicly connected to the sample well, at least one of the channels having a piston and associated micro-valves forming a pump and at least one hollow element, the at least one hollow element being functionalized on its inside surface with a capture moiety or molecules so as to form at least one reaction vessel;the microfluidic channels, micro-valves, and pistons configured to respond to signaling containing information about performing the assay and to controllably receive the sample and at least one reagent through the at least one reaction vessel, and to provide from the at least one reaction vessel light containing information about the assay performed on the sample inside the at least one reaction vessel as a result of said at least one reagent;wherein the hollow element forming the reaction vessel is a section of long strands of hollow tubing that has been cut to 100 to 500 microns in length, the reaction vessels then being functionalized on their inside surface in a batch process in which a plurality of the reaction vessels are coated at once with the same solution of the capture moiety; and wherein free space exists between the outside of the hollow element forming the reaction vessel and the walls of the microfluidic channels.
  • 11. An apparatus according to claim 10, wherein the at least one hollow element is functionalized with the capture moiety or molecules on an inner tubular surface, an outer tubular surface or both surfaces so as to form at least one separate and fluidicly-isolated reaction vessel.
  • 12. An apparatus according to claim 10, where the at least one reaction vessel is contained within a fluidicly-isolated channel.
  • 13. An apparatus according to claim 1, where the at least one hollow element is configured as a honeycomb with multiple axial cavities or chambers.
  • 14. An apparatus for performing an assay, including a chemical or biological assay, on a sample, comprising: at least one sample inlet well configured to receive a sample;microfluidic channels fluidicly connected to the sample well, at least one of the channels having a piston and associated micro-valves forming a pump and at least one hollow element, the at least one hollow element being functionalized on its inside surface with a capture moiety or molecules so as to form at least one reaction vessel;the microfluidic channels, micro-valves, and pistons configured to respond to signaling containing information about performing the assay and to controllably receive the sample and at least one reagent through the at least one reaction vessel, and to provide from the at least one reaction vessel light containing information about the assay performed on the sample inside the at least one reaction vessel as a result of said at least one reagent;the microfluidic channels and micro-valves configured to allow the channels to be fluidicly isolated from each other; andwherein the hollow element forming the reaction vessel is a section of long strands of hollow tubing that has been cut to 100 to 500 microns in length, the reaction vessels then being functionalized on their inside surface in a batch process in which a plurality of the reaction vessels are coated at once with the same solution of the capture moiety.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims benefit to provisional patent application Ser. No. 61/263,572, filed 23 Nov. 2009, which is hereby incorporated by reference in its entirety.

PCT Information
Filing Document Filing Date Country Kind 371c Date
PCT/US2010/057860 11/23/2010 WO 00 9/24/2012
Publishing Document Publishing Date Country Kind
WO2011/063408 5/26/2011 WO A
US Referenced Citations (246)
Number Name Date Kind
3555143 Axen et al. Jan 1971 A
3867517 Ling Feb 1975 A
3876376 Bauman et al. Apr 1975 A
3939350 Kronick et al. Feb 1976 A
4222744 McConnell Sep 1980 A
4254096 Monthony et al. Mar 1981 A
4368047 Andrade et al. Jan 1983 A
4425438 Bauman et al. Jan 1984 A
4447546 Hirschfeld May 1984 A
4517288 Giegel et al. May 1985 A
4690907 Hibino et al. Sep 1987 A
4716121 Block et al. Dec 1987 A
4717545 Morris Jan 1988 A
4797259 Matkovich et al. Jan 1989 A
4820490 Morris Apr 1989 A
4844869 Glass Jul 1989 A
4857453 Ullman et al. Aug 1989 A
4923819 Fernandez et al. May 1990 A
5004923 Hillman et al. Apr 1991 A
5009998 Chow et al. Apr 1991 A
5041181 Brackett et al. Aug 1991 A
5118608 Layton et al. Jun 1992 A
5164598 Hillman et al. Nov 1992 A
5296375 Kricka et al. Mar 1994 A
5302349 Dandliker et al. Apr 1994 A
5304487 Wilding et al. Apr 1994 A
5311275 Taniguchi et al. May 1994 A
5376252 Ekstrom et al. Dec 1994 A
5427946 Kricka et al. Jun 1995 A
5500350 Baker et al. Mar 1996 A
5508200 Tiffany et al. Apr 1996 A
5512151 Hayamizu et al. Apr 1996 A
5517778 Simson May 1996 A
5534328 Ashmead et al. Jul 1996 A
5593290 Greisch et al. Jan 1997 A
5622871 May et al. Apr 1997 A
5624850 Kumar et al. Apr 1997 A
5637469 Wilding et al. Jun 1997 A
5837546 Allen et al. Nov 1998 A
5842787 Kopf-Sill et al. Dec 1998 A
5856174 Lipshutz et al. Jan 1999 A
5861265 Perry Jan 1999 A
5866345 Wilding et al. Feb 1999 A
5876675 Kennedy Mar 1999 A
5882465 McReynolds Mar 1999 A
5885470 Parce et al. Mar 1999 A
5885527 Buechler Mar 1999 A
5886345 Koster et al. Mar 1999 A
5922591 Anderson et al. Jul 1999 A
5932799 Moles Aug 1999 A
5942443 Parce et al. Aug 1999 A
5965237 Bruin et al. Oct 1999 A
5976896 Kumar et al. Nov 1999 A
6008057 Glass et al. Dec 1999 A
6020209 Narang et al. Feb 2000 A
6046056 Parce et al. Apr 2000 A
6048498 Kennedy Apr 2000 A
6068751 Neukermans May 2000 A
6068752 Dubrow et al. May 2000 A
6073482 Moles Jun 2000 A
6082185 Saaski Jul 2000 A
6083763 Balch Jul 2000 A
6086740 Kennedy Jul 2000 A
6103537 Ullman et al. Aug 2000 A
6143152 Simpson et al. Nov 2000 A
6167910 Chow Jan 2001 B1
6197595 Anderson et al. Mar 2001 B1
6214560 Yguerabide et al. Apr 2001 B1
6235241 Catt et al. May 2001 B1
6238538 Parce et al. May 2001 B1
6245296 Ligler et al. Jun 2001 B1
6251343 Dubrow et al. Jun 2001 B1
6267858 Parce et al. Jul 2001 B1
6274337 Parce et al. Aug 2001 B1
6293012 Moles Sep 2001 B1
6306669 Yano et al. Oct 2001 B1
6321791 Chow Nov 2001 B1
6361958 Shieh et al. Mar 2002 B1
6366924 Parce Apr 2002 B1
6383748 Carpay et al. May 2002 B1
6391622 Knapp et al. May 2002 B1
6408878 Unger et al. Jun 2002 B2
6479299 Parce et al. Nov 2002 B1
6494230 Chow Dec 2002 B2
6497155 Feygin et al. Dec 2002 B1
6507989 Bowden et al. Jan 2003 B1
6517778 Kumar et al. Feb 2003 B1
6520753 Grosjean et al. Feb 2003 B1
6524830 Kopf-Sill et al. Feb 2003 B2
6532997 Bedingham et al. Mar 2003 B1
6533914 Liu Mar 2003 B1
6534013 Kennedy Mar 2003 B1
6541213 Weigl et al. Apr 2003 B1
6551841 Wilding et al. Apr 2003 B1
6576478 Wagner et al. Jun 2003 B1
6648015 Chow Nov 2003 B1
6649358 Parce et al. Nov 2003 B1
6649403 McDevitt et al. Nov 2003 B1
6680206 McDevitt et al. Jan 2004 B1
6719868 Schueller et al. Apr 2004 B1
6729352 O'Connor et al. May 2004 B2
6747285 Schueller et al. Jun 2004 B2
6756019 Dubrow et al. Jun 2004 B1
6767194 Jeon et al. Jul 2004 B2
6767706 Quake et al. Jul 2004 B2
6875619 Blackburn Apr 2005 B2
6908737 Ravkin et al. Jun 2005 B2
6908770 McDevitt et al. Jun 2005 B1
6929030 Unger et al. Aug 2005 B2
6960467 Shieh et al. Nov 2005 B2
6994826 Hasselbrink, Jr. et al. Feb 2006 B1
7005292 Wilding et al. Feb 2006 B2
7018830 Wilding et al. Mar 2006 B2
7028536 Karp et al. Apr 2006 B2
7033476 Lee et al. Apr 2006 B2
7040338 Unger et al. May 2006 B2
7087181 Schmidt et al. Aug 2006 B2
7122153 Ho Oct 2006 B2
7125510 Huang Oct 2006 B2
7128910 Tucker et al. Oct 2006 B2
7143785 Maerkl et al. Dec 2006 B2
7144616 Unger et al. Dec 2006 B1
7164533 Moon et al. Jan 2007 B2
7186383 Webster et al. Mar 2007 B2
7189358 Beach et al. Mar 2007 B2
7192559 Chow et al. Mar 2007 B2
7192629 Lammertink et al. Mar 2007 B2
7216671 Unger et al. May 2007 B2
7238269 Gason et al. Jul 2007 B2
7241421 Webster et al. Jul 2007 B2
7250128 Unger et al. Jul 2007 B2
7258837 Yager et al. Aug 2007 B2
7285411 Parce et al. Oct 2007 B1
7294503 Quake et al. Nov 2007 B2
7326561 Goodman et al. Feb 2008 B2
7343248 Parce et al. Mar 2008 B2
7349158 Moon et al. Mar 2008 B2
7351376 Quake et al. Apr 2008 B1
7378280 Quake et al. May 2008 B2
7396674 Miyakawa et al. Jul 2008 B2
7399643 Moon et al. Jul 2008 B2
7419639 Osterfeld et al. Sep 2008 B2
7445926 Mathies et al. Nov 2008 B2
7473562 Van Beuningen et al. Jan 2009 B2
7476363 Unger et al. Jan 2009 B2
7491552 McDevitt et al. Feb 2009 B2
7507588 Mehrpouyan et al. Mar 2009 B2
7622081 Chou et al. Nov 2009 B2
7622083 Amirkhanian et al. Nov 2009 B2
7682565 Linton et al. Mar 2010 B2
7682817 Cohen et al. Mar 2010 B2
7691333 McBride et al. Apr 2010 B2
7695683 Quan et al. Apr 2010 B2
7736890 Sia et al. Jun 2010 B2
7736891 Nelson et al. Jun 2010 B2
7745207 Jovanovich et al. Jun 2010 B2
7754010 Unger et al. Jul 2010 B2
7766033 Mathies et al. Aug 2010 B2
7799553 Mathies et al. Sep 2010 B2
7833708 Enzelberger et al. Nov 2010 B2
7837946 McBride et al. Nov 2010 B2
7843567 Moon et al. Nov 2010 B2
7887750 Blatt et al. Feb 2011 B2
7887753 Quake et al. Feb 2011 B2
7892493 Weekamp Feb 2011 B2
7919172 Schueller et al. Apr 2011 B2
7935489 O'Neill et al. May 2011 B2
7943089 Yang et al. May 2011 B2
7947492 Niehaus May 2011 B2
8049893 Moon et al. Nov 2011 B2
8101403 Yager et al. Jan 2012 B2
8124015 Diercks et al. Feb 2012 B2
8129176 Quake et al. Mar 2012 B2
8147774 Hagiwara et al. Apr 2012 B2
8168139 Manger et al. May 2012 B2
8211657 Li et al. Jul 2012 B2
8236573 Tokhtuev et al. Aug 2012 B2
8277759 Sundberg et al. Oct 2012 B2
20010005489 Roach et al. Jun 2001 A1
20020081744 Chan et al. Jun 2002 A1
20020102742 Parce et al. Aug 2002 A1
20020144738 Unger et al. Oct 2002 A1
20020187560 Pezzuto et al. Dec 2002 A1
20030012693 Otillar et al. Jan 2003 A1
20030032191 Hilson et al. Feb 2003 A1
20030054376 Mullis et al. Mar 2003 A1
20030185713 Leonard et al. Oct 2003 A1
20040101444 Sommers et al. May 2004 A1
20040110199 Montemagno et al. Jun 2004 A1
20040126875 Putnam et al. Jul 2004 A1
20040189311 Glezer et al. Sep 2004 A1
20040200909 McMillan et al. Oct 2004 A1
20040219661 Chen et al. Nov 2004 A1
20040228770 Gandhi et al. Nov 2004 A1
20050098750 Sobek May 2005 A1
20050100943 Kambara et al. May 2005 A1
20050214173 Facer et al. Sep 2005 A1
20050221385 Nikiforov et al. Oct 2005 A1
20050266582 Modlin et al. Dec 2005 A1
20060057576 Paszkowski et al. Mar 2006 A1
20060063271 Putnam et al. Mar 2006 A1
20060073484 Mathies et al. Apr 2006 A1
20060076068 Young et al. Apr 2006 A1
20060207877 Schmidt et al. Sep 2006 A1
20060233668 Resch-Genger et al. Oct 2006 A1
20060257956 Basset et al. Nov 2006 A1
20060263818 Scherer et al. Nov 2006 A1
20060263914 Sando et al. Nov 2006 A1
20060289059 Krylov et al. Dec 2006 A1
20070017633 Tonkovich et al. Jan 2007 A1
20070149863 Padmanabhan Jun 2007 A1
20070224084 Holmes et al. Sep 2007 A1
20070248958 Jovanovich et al. Oct 2007 A1
20080017512 Bordunov et al. Jan 2008 A1
20080035499 Weng Feb 2008 A1
20080131327 Van Dam Jun 2008 A1
20080241858 Metzger et al. Oct 2008 A1
20080280285 Chen et al. Nov 2008 A1
20080311585 Gao et al. Dec 2008 A1
20080311665 Ryan et al. Dec 2008 A1
20090071833 Gorfinkel et al. Mar 2009 A1
20090074623 Park et al. Mar 2009 A1
20090087884 Beerling et al. Apr 2009 A1
20090148933 Battrell et al. Jun 2009 A1
20090181411 Battrell et al. Jul 2009 A1
20090215158 Sekizawa et al. Aug 2009 A1
20090253181 Vangbo et al. Oct 2009 A1
20090257920 Facer et al. Oct 2009 A1
20090325171 Hirt et al. Dec 2009 A1
20090325276 Battrell et al. Dec 2009 A1
20100101670 Juncker et al. Apr 2010 A1
20100167384 Clemmens et al. Jul 2010 A1
20100173394 Colston, Jr. et al. Jul 2010 A1
20100186841 Mukaddam et al. Jul 2010 A1
20100216248 Wardlaw Aug 2010 A1
20100221814 Asogawa et al. Sep 2010 A1
20100233791 Sim et al. Sep 2010 A1
20100303687 Blaga et al. Dec 2010 A1
20110008776 Warthoe et al. Jan 2011 A1
20110020947 Bedingham et al. Jan 2011 A1
20110105361 Moon et al. May 2011 A1
20110195260 Lee et al. Aug 2011 A1
20110262940 Hisamoto et al. Oct 2011 A1
20110306081 Szita et al. Dec 2011 A1
20120164036 Stern et al. Jun 2012 A1
20120266986 Wimberger-Friedl et al. Oct 2012 A1
Foreign Referenced Citations (59)
Number Date Country
1189449 Jun 1985 CA
3226407 Jan 1984 DE
0401033 Dec 1990 EP
1415788 May 2004 EP
1404448 Sep 2006 EP
1936382 Jun 2008 EP
2284538 Feb 2011 EP
2463666 Jun 2012 EP
2155152 Sep 1985 GB
94100467 Jun 1996 GR
09288089 Nov 1997 JP
2001-157855 Jun 2001 JP
2003-507737 Feb 2003 JP
2005-140681 Jun 2005 JP
2007-516419 Jun 2007 JP
122612 Sep 2009 RO
9204613 Mar 1992 WO
9737803 Oct 1997 WO
9911754 Mar 1999 WO
9944217 Sep 1999 WO
0107889 Feb 2001 WO
0114865 Mar 2001 WO
03004160 Jan 2003 WO
03042677 May 2003 WO
2004000721 Dec 2003 WO
2004034028 Apr 2004 WO
2004041061 May 2004 WO
2004059299 Jul 2004 WO
2004061085 Jul 2004 WO
2005066613 Jul 2005 WO
2005107938 Nov 2005 WO
2006071470 Jul 2006 WO
2007021813 Feb 2007 WO
2007032316 Mar 2007 WO
2007033385 Mar 2007 WO
2007044091 Apr 2007 WO
2007092713 Aug 2007 WO
2007093939 Aug 2007 WO
2007106579 Sep 2007 WO
2007117987 Oct 2007 WO
2007136715 Nov 2007 WO
2008032128 Mar 2008 WO
2008043046 Apr 2008 WO
2008075253 Jun 2008 WO
2008089493 Jul 2008 WO
2008115626 Sep 2008 WO
2008154036 Dec 2008 WO
2009012340 Jan 2009 WO
2009029177 Mar 2009 WO
2009088408 Jul 2009 WO
2009105711 Aug 2009 WO
2010017210 Feb 2010 WO
2010027812 Mar 2010 WO
2010057078 May 2010 WO
2010077618 Jul 2010 WO
2010148252 Dec 2010 WO
2011040884 Apr 2011 WO
2011053845 May 2011 WO
2012129455 Sep 2012 WO
Non-Patent Literature Citations (33)
Entry
Cooksey et al., “A vacuum manifold for rapid world-to-chip connectivity of complex PDMS microdevices,” Lab on a Chip, vol. 9, No. 9 (Jan. 1, 2009).
Grover et al., “Teflon films for chemically-inert microfluidic valves and pumps,” Lab on a Chip, vol. 8, No. 6 (Jan. 1, 2008).
Hicks, Jocelyn M., “Fluorescence Immunoassay,” from “Human Pathology”, vol. 15, No. 2, Feb. 1984, pp. 112-116 (5 pages).
Fayram, Sandra L., “Fluorescence Immunoassay and Passive Latex Agglutination as Alternatives to Hemagglutination Inhibition for Determining Rubella Immune Status,” from “Journal of Clinical Microbiology,” vol. 17, No. 4, Apr. 3, 1983, pp. 685-688 (4 pages).
Ozinskas, Alvydas J., “Principles of Fluorescence Immunoassay,” from “Topics in Fluorescence Spectroscopy, vol. 4: Probe Design and Chemical Sensing,” 1994, pp. 449-496 (48 pages).
Japanese Office Action; JP 2012-540157; Aug. 6, 2013; 7 pp.
Chaudhury and Whitesides, 1991,“Direct Measurement of Interfacial Interactions Between Semispherical Lenses and Flat Sheets of Poly(dimethylsiloxane) and Their Chemical Derivatives”, p. 1021: Interaction between Oxidized PDMS Surfaces.
Delamarche et al, “Patterned Delivery of Immunoglobulins to Surfaces Using Microfluidic Networks”, Science, vol. 276, p. 779-781, (submitted Dec. 30, 1996).
Duffy, et al, “Rapid Prototyping of Microfluidic Systems in Poly (dimethylsiloxane)”, Anal. Chem vol. 70, No. 23,1998, 4974-4984.
Effenhauser et al, “Integrated Capillary Electrophoresis on Flexible Silcione Microdevices; Analysis of DNA . . . ”, Analytical Chemistry, vol. 69, No. 17, 3451-7.
Folta et al, “Design, Fabrication and Testing of a Miniature Peristaltic Membrane Pump”, 1992, Technical Digest IEEE Solid-State Sensors and Actuators Workshop, pp. 186-189.
Fujii et al., Bulk- and Surface-Modified Combinable PDMS Capillary Sensor Array as an Easy-to-Use Sensing Device with Enhanced Sensitivity to Elevated Concentrations of Multiple Serum Sample Components, Lab Chip 12:1522 (2012).
Henares et al., “Current Development in Microfluidic Immunosensing Chip,” Analytica Chimica Acta 611:17-30 (2008).
Henares et al., “Development of Single-Step Heterogenous Sandwich Capillary Immunosensor for Capillary-Assembled Microchip (CAs-CHIP) Integration,” Twelfth International Conference on Miniaturized Systems for Chemistry and Life Sciences, San Diego, California (Oct. 12-16, 2008).
Henares et al., “Enzyme-Release Capillary as a Facile Enzymatic Biosensing Part for a Capillary-Assembled Microchip,” Analytical Sciences 25:1025-1028(Aug. 2009).
Henares et al., “Multiple Enzyme Linked Immunosorbent Assay System on a Capillary-Assembled Microchip Integrating Valving and Immuno-Reaction Functions,” Analytica Chimica Acta 589:173-179 (2007).
Henares et al., “Single-Drop Analysis of Various Proteases in a Cancer Cell Lysate Using a Capillary-Assembled Microchip,” Anal Bioanal Chem 391:2507-2512 (2008).
Henares et al., “Single-Step ELISA Capillary Sensor Based on Surface-Bonded Glucose Oxidase, Antibody, and Physically-Adsorbed PEG Membrane Containing Peroxidase-Labeled Antibody,” Sensors and Actuators B 149:319-324 (2010).
Hisamoto et al., “Capillary-Assembled Microchip as an On-Line Deproteinization Device for Capillary Electrophoresis,” Anal Bioanal Chem 386:733-738 (2006).
Hisamoto et al., “Capillary-Assembled Microchip for Universal Integration of Various Chemical Functions onto a Single Microfluidic Device,” Anal. Chem. 76:3222-3228 (2004).
Hisamoto et al., “Integration of Multiple-Ion-Sensing on a Capillary-Assembled Microchip,” Analytica Chimica Acta 556:164-170 (2006).
Hisamoto et al., “Integration of Valving and Sensing on a Capillary-Assembled Microchip,” Anal. Chem. 77:2266-2271 (2005).
Hosokawa, K. and Maeda, R., “A normally closed PDMS (polydimethylsiloxane) microvalve”, T.IEE Japan, vol. 120-E, No. 4, 2000.
Hosokawa, K, and Maeda, R., “A pneumatically-actuated three-way microvalve fabricated with polydimethysiloxane using the membrane transfer technique”, J. Mickromecjh. Microeng. 10 (2000) 415-420.
Lammerink, et al “Modular Concept for Fluid Handling Systems—A demonstrator Micro Analysis System”, 1996, Proc. IEEE Micro Electro Mechanical Systgems Workshop, San Diego CA, Feb. 1996, pp. 389-394.
Macdonald and Whitesides, “Poly(dimethylsilocane) as a Material for Fabricating Microfluidic Devices”, 2002.
Madou, Fundamentals of Microfabrication, CRC Press, 1997, pp. 382-394 especially p. 390.
Shoji et al, “Microflow Devices and Systems”, 1994, J. Micromech. Microeng. 4 (1994) 157-171.
Smits, “Piezoelectric Micropump with Three Valves Working Peristaltically”, 1990, Sensors and Actuators, A21-23 (1990) 203-206.
Yacoub-George et al., “Automated 10-Channel Capillary Chip Immunodetector for Biological Agents Detection,” Biosensors and Bioelectronics 22:1368-1375 (2007).
Supplementary European Search Report from corresponding European Appn. No. 10832371.8 dated Jul. 22, 2013.
Supplementary European Search Report dated Nov. 5, 2014 for Application No. 12760266.2.
European Communication dated Nov. 21, 2014 for Application No. 12760266.2.
Related Publications (1)
Number Date Country
20130011859 A1 Jan 2013 US
Provisional Applications (1)
Number Date Country
61263572 Nov 2009 US